RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Khosrow Kashfi to Colonic Neoplasms

This is a "connection" page, showing publications Khosrow Kashfi has written about Colonic Neoplasms.
Connection Strength

1.576
  1. Vannini F, Kodela R, Chattopadhyay M, Kashfi K. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism. Redox Biol. 2015 08; 5:421.
    View in: PubMed
    Score: 0.408
  2. Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PP, Nia KV, Vel?zquez-Mart?nez CA, Kashfi K. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition. J Pharmacol Exp Ther. 2013 Apr; 345(1):85-94.
    View in: PubMed
    Score: 0.333
  3. Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012 Mar 16; 419(3):523-8.
    View in: PubMed
    Score: 0.312
  4. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther. 2005 Mar; 312(3):978-88.
    View in: PubMed
    Score: 0.188
  5. Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-?B signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 2010 Dec 08; 298(2):204-11.
    View in: PubMed
    Score: 0.070
  6. Gao J, Kashfi K, Liu X, Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis. 2006 Apr; 27(4):803-10.
    View in: PubMed
    Score: 0.050
  7. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol. 2005 Oct 01; 70(7):993-1000.
    View in: PubMed
    Score: 0.050
  8. Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans. 2005 Aug; 33(Pt 4):701-4.
    View in: PubMed
    Score: 0.050
  9. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 2003 Nov 15; 63(22):7613-8.
    View in: PubMed
    Score: 0.044
  10. Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat. 2002 Feb; 67(2):107-20.
    View in: PubMed
    Score: 0.039
  11. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol. 2004 Jun 15; 67(12):2197-205.
    View in: PubMed
    Score: 0.011
  12. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun. 2004 Jan 16; 313(3):784-8.
    View in: PubMed
    Score: 0.011
  13. Nath N, Kashfi K, Chen J, Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12584-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support